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tively. In addition, in the presence of 0.75 eccentricity, the maximum
principal stress value in the commissures was increased by 173%, 213%
and 149%, as compared to circular TAV expanded to 23, 21, and 19mm,
respectively.
CONCLUSIONS Computational models were developed to study the
synergistic impact of incomplete and eccentric TAV stent expansion on
leaﬂet stress distributions. Eccentric and incomplete stent deployment
induce localized high stress regions within the TAV leaﬂets. Increased
mechanical stress on TAV leaﬂets may lead to accelerated tissue
degeneration and diminished long-term valve durability.
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BACKGROUND The sequential implantation of a transcatheter heart
valve (THV) within a similar device, also known as valve-in-valve-in-
valve, will be an important concept in the future, considering patients
with elevated surgical risk and failed THVs within surgical aortic
valves (SAV). However, this procedure has not been studied in depth,
especially considering the reduction of effective oriﬁce area (EOA) and
the elevation of transvalvular gradients (DP). Our objective was to
evaluate the hydrodynamic performance of valve-in-valve-in-valve,
determining the therapeutic limits.
METHODS Using a pulse duplicator, three sets of valve-in-valve-in-
valve were tested. FDA speciﬁcations for cardiac output, mean arterial
pressure and heart rate variation were used. EOA and DP were
measured. First set was a 23mm surgical valve with two sequential
THV implants of 22mm and 20mm. Second set was a 25mm surgical
valve with two sequential THV implants of 24mm and 22mm. The last
set was a 25mm surgical valve with three sequential implants of
24mm, 22mm and 20mm.
RESULTS The results obtained from the three sets are represented on
Table 1.EOA (cm2) DP (mmHg)20mm THV within 22mm THV
within 23mm SAV0.97 12.822mm THV within 24mm THV
within 25mm SAV0.97 13.4620mm THV within 22mm THV
within 24mm THV within
25mm SAV0.86 15.32CONCLUSIONS The use of multiple THVs as an alternative to
repeated conventional aortic valve replacement can be considered
feasible after hydrodynamic testing. Satisfactory results can be ob-
tained with up to 22mm THVs. When a 20mm THV was needed, re-
sults were borderline to prohibitive, depending on whether it was the
2nd or 3rd implantation. The less-than-optimal results might be due to
device underexpansion.
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BACKGROUND There is limited data, especially from the US, on sex-
related differences with regards to patient characteristics and out-
comes with the CoreValve prosthesis. The objective of this study is to
compare the baseline characteristics and clinical outcomes in women
and men undergoing transcatheter aortic valve replacement with the
CoreValve prosthesis in the United States.
METHODS Patients used for this analysis include all patients who
underwent TAVR in any one of the 4 CoreValve US trials- the Cor-
eValve Pivotal extreme and high risk trials as well as the CoreValve
Continued Access extreme and high risk trials. Data from 3687 pa-
tients including 1708 women and 1979 men undergoing TAVR were
included for analysis.
RESULTS Women comprised 46% of the ﬁnal cohort and at baseline
had a higher STS score (9.6% vs. 8.3%). While there was no difference
in baseline NYHA classiﬁcation, women tended to have fewer cardiac
comorbidities and a lower rate of coronary artery disease including
fewer MIs, CABGs, and PCIs. Women were also less likely to have
peripheral vascular disease, a pre-existing pacemaker, or a prior
stroke. Conversely, women had increased frailty indices as measured
by KATZ ADL deﬁcits, walk times, and grip strength. At baseline
women had a higher mean gradient across the aortic valve (51.5 vs
44.3mmHg) and smaller EOA (0.66 vs. 0.79cm2). From a procedural
standpoint, women were slightly more likely to require alternative
access (21% vs 18.35%) and tended to receive smaller sized valves. The
30-day and 1-year outcomes are summarized in the table below.
CONCLUSIONS Women, who account for nearly half of the population
undergoing TAVR within the CoreValve US trials, tend to have fewer
cardiac comorbidities and increased frailty as compared to men. While
differences exist in procedural risks between men and women un-
dergoing TAVR with the CoreValve prosthesis, there was no difference
in 30-day or 1-year mortality.30 -days 1 yearMale
(N[1979)Female
(N[1708) P-valueMale
(N[1979)Female
(N[1708) P-valueAll-Cause Mortality, % 114 (5.8) 100 (5.9) 0.87 406 (24.1) 315 (21.3) 0.08Cardiovascular, % 109 (5.6) 98 (5.8) 0.74 305 (18.1) 242 (16.4) 0.23Stroke, % 79 (4.0) 95 (5.7) 0.02 129 (7.7) 141 (9.3) 0.05Major, % 42 (2.1) 60 (3.6) 0.01 72 (4.5) 86 (5.6) 0.04All-Cause Mortality or
Major Stroke, %142 (7.2) 140 (8.2) 0.22 434 (25.6) 353 (23.4) 0.32Bleed, % 615 (31.2) 728 (42.7) <0.0001 694 (36.7) 781 (46.8) <0.0001Life-Threatening/
disabling, %200
(10.2)244 (14.3) 0.0001 261 (14.3) 290 (17.9) 0.002Major Vascular
Complication, %96 (4.9) 165 (9.7) <0.0001 103 (5.3) 168 (9.9) <0.0001Acute Kidney Injury, % 222 (11.3) 175 (10.4) 0.38 222 (11.3) 175 (10.4) 0.38Myocardial Infarction,
%16 (0.8) 18 (1.1) 0.43 33 (2.1) 34 (2.4) 0.52Cardiac Tamponade, % 11 (0.6) 42 (2.5) <0.0001 15 (0.8) 43 (2.5) <0.0001New Permanent
Pacemaker
Implant, %453 (23.2) 311 (18.6) 0.0007 508
(27.0)346 (21.4) 0.0001KCCQ Overall
Summary Score
Change from
Baseline22.4 
27.422.4 
27.20.96 28.0 
28.128.9 
26.40.53
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BACKGROUND The presence of acute renal injury (AKI) enhances
morbimortality after surgical aortic valve. However, the risk of peri-
procedural AKI and its association with outcomes after transcatheter
aortic valve replacement (TAVR) is still incompletely understood. This
prospective observational study aims to determine the incidence of
AKI, its predictors and impact on 30-days and 1-year mortality.
METHODS We assessed data from 225 consecutive patients with se-
vere symptomatic aortic stenosis submitted to TAVR between January
2009 and February 2015 on two tertiary cardiologic centers, conducted
by the same heart team. All patients used an ionic, low-osmolar, low-
viscosity contrast. Kidney injury was deﬁned according to VARC
(Valve Academic Research Consortium) criteria, following AKIN sys-
tem, and analyzing data until the seventh day post-procedure. Three
patients were excluded due to death during the procedure, consid-
ering those deaths not related to renal dysfunction. One patient was
excluded due to incomplete data. The remaining 221 patients
comprised the population of the current analysis separated in two
groups: AKI group (group 1) and non-AKI group (group 2). Follow-up
was performed on 30 days and after one year.
RESULTS At baseline, mean age was 82.24  6.78 years, 53% women,
transfemoral access 75.6%. Fifty two patients (23.5%) developed AKI
until seventh day of procedure. Groups 1 and 2 were similar, except
for EuroSCORE II (8.66%  5.64% vs 7.34%  8.58%, p ¼ 0.02) and
glomerular ﬁltration rate (GFR) (39.59 ml/min.1.73m2  13.62 vs. 48.49
 19.6, p ¼ 0.002). Overall 30 days-mortality and 1-year mortality was
6.3% and 14.0%, respectively. Both 30-day mortality (23.1% vs 1.2%,
p < 0.001) and 1-year mortality (44.2% vs 4.7%, p< 0.001) were higher
in group 1. In multivariable-adjusted models, the only independent
predictor for AKI after TAVR was baseline GFR [hazard ratio (HR) 1.37,
CI 95% 1.08-1.77, p ¼ 0.01]. Regarding long term follow-up, AKI (HR
19.86, CI 95% 7.31-53.98, p <0.001) and COPD (HR 3.14, IC 95% 1.05-
9.40, p ¼ 0.04) were independent risk factors for 1-year mortality,
whilst hypertension (HR 0.269, 0.09-0.80, p ¼ 0.01) was shown to be
protective for long term mortality.
CONCLUSIONS In this TAVR sample, baseline GFR was the only in-
dependent predictor of AKI, and patients who developed it had
signiﬁcantly higher mortality at 30 days and 1 year. Acute renal
impairment was the strongest risk factor for mortality and adverse
cardiovascular events that provided risk information beyond the
traditional scores, as EuroSCORE II and STS. Careful identiﬁcation of
risk factors and development of more suitable risk scores is essential.
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BACKGROUND Following transcatheter aortic valve Implantation
(TAVI), patients are usually monitored by telemetry for a few days.
However, there is currently no consensus on the duration of telem-
etry, and some patients may not require telemetry at all. In the pre-
sent study, we sought to evaluate how the postprocedural ECG
determines the need for pacemaker implantation and optimal dura-
tion of telemetry monitoring.
METHODS Patients without a permanent pacemaker undergoing TAVI
at two centers in Switzerland were investigated. ECGs at baseline and
post TAVI were analyzed to identify atrioventricular and interven-
tricular conduction disorders. A normal ECG was deﬁned as a QRS
width < 120 ms and a PQ time < 200 ms. The occurrence and timing of
high degree atrioventricular block (AVB) and the need for Implanta-
tion of a permanent pacemaker was recorded.
RESULTS A total of 537 patients underwent TAVI with either the
CoreValve (n ¼ 265) or the SAPIEN XT or SAPIEN 3 (n¼ 272). None of
the patients with a normal postprocedural ECG developed high degree
atrioventricular block (AVB) or required implantation of a permanent
pacemaker. Patients with a narrow QRS but impaired AV conduction
required a pacemaker in 6/58 (9.4%), and heart block occurred as late
as 3 days post procedure. Patients with a wide QRS and normal AV
conduction required a pacemaker in 17/154 (11.0%) and heart block
occurred up to 2 days post procedure. Patients with a wide QRS and
impaired AV conduction required a pacemaker in 24/61 (39.3%) and
heart block occurred as late as 5 days post procedure. Almost all pa-
tients (60/61, 98.4%) with a complete heart block post procedure
required implantation of a permanent pacemaker.
CONCLUSIONS The postprocedural ECG was predictive of the
required duration of telemetry monitoring regardless of the type of
valve implanted. Patients with a normal ECG post TAVI did not
develop high-degree heart block and did not require implantation of a
permanent pacemaker. Such patients do not require telemetry and
may be candidates for early discharge. Telemetry monitoring of 2 days
should be considered for patients with wide QRS post TAVI. Patients
with impaired AV conduction post TAVI required up to 5 days of
telemetry monitoring. The ﬁndings of this study may help to improve
in-hospital management of TAVI patients and reduce costs associated
with this procedure.
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BACKGROUND The SAPIEN 3 (Edwards Lifescience) balloon-expand-
able valve incorporates a paravalvular sealing system, an active 3-
dimensional coaxial positioning catheter, and is compatible with a 14-
F expandable sheath. These characteristics provide a theoretical su-
periority over previous device, including feasibility of TAVR (trans-
catheter aortic valve replacement) in a broader range of patients,
better accuracy in valve positioning and less paravalvular regurgita-
tion. We aimed to evaluate short-term outcomes in TAVR patients
who beneﬁted from 3rd generation SAPIEN 3 valve implantation and
to compare these results to those obtained with the earlier generation
SAPIEN XT device.
METHODS This single center prospective study included all patients
who underwent TAVR with balloon-expandable SAPIEN valve
